SCHEMBL14901480

SCHEMBL14901480

COCC(O)COc1ccc(Sc2ccc(OCC(O)COC)cc2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 4/20 0.50
MAPT P10636 2/20 0.50
LMNA P02545 2/20 0.50
NPSR1 Q6W5P4 2/20 0.50
NR3C1 P04150 1/20 0.46
ADRB2 P07550 1/20 0.46
ADRB1 P08588 1/20 0.46
CYP2D6 P10635 1/20 0.46
ADRA1A P35348 1/20 0.46
CYP2J2 P51589 1/20 0.46
PDE4D Q08499 1/20 0.46
SMN1; SMN2 Q16637 4/20 0.45
ALDH1A1 P00352 2/20 0.45
PLA2G4B P0C869 1/20 0.43
KDM4E B2RXH2 2/20 0.42
GAA P10253 1/20 0.42
HPGD P15428 1/20 0.42
GLA P06280 1/20 0.41
USP2 O75604 1/20 0.41
TSHR P16473 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14901486 0.91 ADRB2 (0.43) POLBMAPTLMNANPSR1NR3C1
SCHEMBL14901491 0.86 PLA2G4B (0.46) POLBMAPTLMNANPSR1NR3C1
SCHEMBL14546451 0.84 LMNA (0.53) POLBMAPTLMNANPSR1ADRB2
SCHEMBL14901479 0.83 POLB (0.55) POLBMAPTLMNANPSR1NR3C1
SCHEMBL14901482 0.83 POLB (0.55) POLBMAPTLMNANPSR1NR3C1
SCHEMBL12133451 0.81 USP2 (0.60) POLBMAPTLMNANPSR1NR3C1
SCHEMBL890956 0.81 AR (0.51) POLBMAPTLMNANPSR1CYP2D6
SCHEMBL28531572 0.80 POLB (0.51) POLBMAPTLMNANPSR1NR3C1
SCHEMBL14565150 0.80 MAPT (0.43) POLBMAPTLMNANPSR1CYP2D6
SCHEMBL20898870 0.80 MAPT (0.59) POLBMAPTLMNANPSR1NR3C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130109758-A1 BISPHENOL DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2013-05-02 US disclosed
US-20130109758-A1 BISPHENOL DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2013-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130109758-A1 BISPHENOL DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE SHBG, KLK3, HSD17B11 POLB 388/4885MAPT 1962/4885LMNA 1050/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.